New scientific publication by AroCell accepted by BioTechniques journal

AroCell AB announces today that a new peer-reviewed article has been accepted for publication in the BioTechniques journal. The article describes a comparison of AroCell TK 210 ELISA with Abcam TK1 ELISA.

The article is entitled “AroCell TK 210 ELISA for determination of TK1 protein: Age-related reference ranges and comparison with other TK1 assays”, by Kiran Jagarlamudi et al. The aim of the study is to establish the age-related reference ranges of TK1 protein levels in sera from apparently healthy individuals (N=264), and comparison of AroCell TK 210 ELISA with Abcam TK1 ELISA using sera from patients with hematological malignancies (N=62) as well as solid tumours (N=30).

The results of this scientific study demonstrated that the AroCell TK 210 ELISA has higher sensitivity than the Abcam TK1 ELISA for differentiating hematological malignancies and solid tumors from apparently healthy individuals. These results strongly indicate that the AroCell TK210 ELISA is accurate and sensitive enough to be a valuable tool in cancer management compared to other TK1 assays.

“We are delighted with the results of this scientific study, which demonstrate that the AroCell TK 210 ELISA kit has high accuracy and sensitivity compare to other methods”, Michael Brobjer CEO at AroCell.

The publication will soon be available on biotechniques.com and on arocell.com.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the late G1 phase and early S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example therapeutic agents.

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

New scientific publication by AroCell accepted by BioTechniques journal